Genetic Signatures Ltd (ASX: GSS) Share Price and News

Ms Waldron is a cross border advisor and director with over 30 years expertise in governance, marketing, human resources, and digital transformation across a range of sectors. She has been admitted to the Bar of England and Wales and the courts of other jurisdictions including Australia and New Zealand. She is member of the Risk & Compliance Committee.

Dr Harry has 25 years of experience in executive roles and as an independent Director in leading early stage companies to develop and commercialise innovative products. She co founded Proteome Systems Limited with the team who pioneered the scientific field of proteomics and commercialised a suite of disruptive technologies including reagents, instrumentation and software in Australia, the USA and Japan. As CEO of Tyrian Diagnostics Ltd she secured agreements with multinational companies for the development and commercialisation of agricultural and clinical diagnostic products. She is Chair Technology Committee and Member of the Risk & Compliance Committee

Mr. Aicher has over 30 years of industry experience and was CEO and founder of National Genetics Institute (NGI) which was acquired by Laboratory Corporation of America, Inc. (LabCorp) in 2000. He led LabCorps Esoteric Business Units, which generated more than $1 billion in annual revenue. Prior to NGI, he served in a number of executive leadership roles at Central Diagnostics Laboratory. He currently serves as a director on boards of SemiconBio, SOLVD and Techcyte. He is certified by the University of California at Berkeley as a Global Biotechnology Executive and is a recipient of Ernst & Youngs Entrepreneur of the Year award for emerging technologies. He is Member of the Technology Committee.

Dr Gunn has over 30 years of experience in medical devices and diagnostics. Most recently he was CEO of IDbyDNA, a metagenomics company based in the US that was acquired by Illumina in 2022. Prior to this he was the President of Roche Sequencing Solutions where he oversaw all aspects of the business and managed a team of approximately 900 people. His team developed and launched more than 20 products per year. He was also previously Vice President of Roches Molecular Diagnostics business and was responsible for over 120 diagnostic product launches principally into the IVD clinical market. He is Member of the Technology Committee.

Mrs Lockwood has over 33 years of experience in various finance, risk management and audit roles including deep experience in mergers and acquisitions across a range of industries. Prior to this, she spent over 20 years in accounting and audit roles including 18 years at Andersens and EY. She is Chair of the Risk & Compliance Committee.

-

-

-

-